Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Leases (2019 - 2023)

Ascendis Pharma A's Current Leases history spans 5 years, with the latest figure at $15.3 million for Q4 2023.

  • For Q4 2023, Current Leases rose 8.52% year-over-year to $15.3 million; the TTM value through Dec 2023 reached $15.3 million, up 8.52%, while the annual FY2023 figure was $15.4 million, 5.61% up from the prior year.
  • Current Leases for Q4 2023 was $15.3 million at Ascendis Pharma A, up from $14.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $15.3 million in Q4 2023 and bottomed at $6.5 million in Q4 2019.
  • The 5-year median for Current Leases is $8.2 million (2020), against an average of $10.4 million.
  • The largest annual shift saw Current Leases decreased 2.15% in 2021 before it surged 75.95% in 2022.
  • A 5-year view of Current Leases shows it stood at $6.5 million in 2019, then grew by 25.25% to $8.2 million in 2020, then decreased by 2.15% to $8.0 million in 2021, then surged by 75.95% to $14.1 million in 2022, then grew by 8.52% to $15.3 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Current Leases are $15.3 million (Q4 2023), $14.1 million (Q4 2022), and $8.0 million (Q4 2021).